Eric I Tsao

Dr. Eric Tsao has served as the Chief Executive Officer of Synermore Biologics since the founding of the company in 2013. He has over 25 years of industrial experience with Johnson and Johnson, AstraZeneca, and Morningside Group. His areas of expertise include biological product development, process design, facility engineering, and operations. Dr. Tsao received his Ph.D. in Chemical Engineering from the University of Michigan. 2026 Oral Presentation (In-Person) Title: SYN023 mAb cocktail for rabies prophylaxis 2026 Oral Presentation (In-Person) Title: Broad neutralization spectrum of SYN023, A humanized anti-rabies monoclonal antibody cocktail, validated by pseudovirus analyses